钠-葡萄糖协同转运蛋白-2抑制剂治疗心力衰竭的进展

The progress of heart failure treatment with sodium-dependent glucose transporters 2 inhibitor

2021年8月欧洲心脏协会(European Society of Cardiology, ESC)和2022年4月美国心脏协会(American Heart Association, AHA)/美国心脏病学会(American College of Cardiology, ACC)/美国心力衰竭学会(Heart Failure Society of America, HFSA)相继对心力衰竭诊断和治疗指南进行了更新, 其中钠-葡萄糖协同转运蛋白-2(sodium-dependent glucose transporters 2 inhibitor, SGLT-2)抑制剂(SGLT-2 inhibition, SGLT-2i)在左室射血分数降低型心力衰竭(heart failure with reduced ejection fraction, HFrEF)、射血分数轻度降低型心力衰竭(heart failure with mildly reduced ejection fraction, HFmrEF)和射血分数保留型心力衰竭(heart failure with preserved ejection fraction, HFpEF)的治疗中均有较高等级推荐。